Evaluation of the genotoxicity of the imidazole antifungal climbazole: Comparison to published results for other azole compounds

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 672, Issue 1, 2009, Pages 27-39

  Pérez Rivera, Alex A ^a   Hu, Ting ^a   Aardema, Marilyn J ^a   Nash, J F ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Ames; Azole antifungals; Climbazole; Genotoxicity; In vitro and in vivo micronucleus; Mouse lymphoma L5178Y; Unscheduled DNA synthesis

Indexed keywords

CARBON 14; CLIMBAZOLE; CYCLOPHOSPHAMIDE; DIMETHYLNITROSAMINE; IMIDAZOLE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; LIVER TOXICITY; LYMPHOCYTE; LYMPHOMA CELL; MALE; MAXIMUM TOLERATED DOSE; METABOLIC ACTIVATION; MICRONUCLEUS TEST; MOUSE; MUTAGEN TESTING; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RISK ASSESSMENT; SEX DIFFERENCE; TOXICITY TESTING; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BONE MARROW; DNA; HUMANS; IMIDAZOLES; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED ICR; MICRONUCLEUS TESTS; MODELS, CHEMICAL; MUTAGENICITY TESTS; MUTAGENS; RATS; SALMONELLA TYPHIMURIUM; TIME FACTORS;

ESCHERICHIA COLI; MUS; RATTUS; SALMONELLA TYPHIMURIUM;

EID: 57649087472     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2008.09.011     Document Type: Article

References (42)

1. Sheehan D.J., Hitchcock C.A., and Sibley C.M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12 (1999) 40-79
2. Maertens J.A. History of the development of azole derivatives. Clin. Microbiol. Infect. 10 Suppl. 1 (2004) 1-10
3. Como J.A., and Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330 (1994) 263-272
4. Dossier on Climbazole (COLIPA No. P64) Submission II, June 19, 2007.
5. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals, Fed. Regist. 62 (1997) 16026-16030.
6. Muller L., Kasper P., and Schechtman L. ICH guidances on genotoxicity and carcinogenicity: scientific background and regulatory practice. In: Choy W.N. (Ed). Genetric Toxicology and Cancer Risk Assessment (2001), Marcel Dekker, New York, NY 187-221
7. Scientific Committee on Consumer Products and Non-Food Products Intended for Consumers (SCCP), Recommended mutagenicity/genotoxicity tests for the safety testing of cosmetic ingredients to be included in the annexes to council directive 76/768/EEC, Adopted by the SCCNFP during the 26th plenary meeting of December 9, 2003.
8. Yahagi T., Nagao M., Seino Y., Matsushima T., and Sugimura T. Mutagenicities of N-nitrosamines on Salmonella. Mutat. Res. 48 (1977) 121-129
9. Ames B.N., McCann J., and Yamasaki E. Methods for detecting carcinogens and mutagens with Salmonella/mammalian microsome mutagenicity test. Mutat. Res. 31 (1975) 347-364
10. Maron D.M., and Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113 (1983) 173-215
11. Clive D., Caspary W., Kirkby P., Krehl R., Moore M., Mayo J., and Oberly T. Guide for performing the mouse lymphoma assay for mammalian cell mutagenicity. Mutat. Res. 189 (1987) 143-156
12. Moore M.M., Honma M., Clements J., Bolcsfoldi G., Burlinson B., Cifone M., Clarke J., Delongchamp R., Durward R., Fellows M., Gollapudi B., Hou S., Jenkinson P., Lloyd M., Majeska J., Myhr B., O'Donovan M., Omori T., Riach C., San C., Stankowski L., Thakur Jr. F., Van Goethem A.K., Wakuri F., and Yoshimura I S. Mouse lymphoma thymidine kinase gene mutation assay: follow-up meeting of the international workshop on genotoxicity tests-Aberdeen, Scotland, 2003. Environ. Mol. Mutagen. 47 (2006) 1-5
13. Kennelly J., Lefevre P., Dean S., et al. In vivo Rat Liver UDS Assay. In Report of the UKEMS Sub-committee on Guidelines for Mutagenicity Testing, Part II Revised (1993), Cambridge University Press, Cambridge, UK pp. 52-77
14. Butterworth B.E., Ashby J., Bermudez E., Casciano D., Mirsalis J., Probst G., and Williams G. A protocol and guide for the in vivo rat hepatocyte DNA-repair assay. Mutat. Res. 189 (1987) 123-133
15. Honma M., Zhang L., Sakamoto H., Ozaki M., Takashita K., Momose M., Hayashi M., and Sofuni T. The need for long-term treatment in the mouse lymphoma assay. Mutagenesis 14 (1999) 23-29
16. Yuzbasioglu D., Unal F., Yilmaz S., Aksoy H., and Celik M. Genotoxicity testing of fluconazole in vivo and in vitro. Mutat. Res. 649 (2008) 155-160
17. Larson N., Marklund U., Gradin H., Brattsand G., and Gullberg M. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol. Cell. Biol. 17 (1997) 5530-5539
18. Walker K.A., Braemer A.C., Hitt S., Jones R.E., and Matthews T.R. 1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent. J. Med. Chem. 21 (1978) 840-843
19. Oxiconazole (Monograph) Mosby's Drug Consult. Oxiconazole Nitrate, 17th ed. (2007) II 2180-II 2181, 16th edition, Mosby Elsevier, St. Louis, MO, 2006.
20. Sulconazole (Monograph) AHFS Drug Information 2008. Sulconazole Nitrate. 1 (2008) 3528-3531, American Society of Health-System Pharmacists, Bethesda, MD, 2007.
21. Ticoconazole (Monograph) AHFS Drug Information 2008. Tioconazole. 1 (2008) 3534-3537, American Society of Health-System Pharmacists, Bethesda, MD, 2007.
22. Voogd C.E., and van der Stel J.J. Are econazole, miconazole and clotrimazole mutagenic to bacteria?. Mutat. Res. 120 (1983) 91-95
23. Ketoconazole (Monograph) AHFS Drug Information 2008, Ketoconazole 1 (2008) 3520-3522, American Society of Health-System Pharmacists, Bethesda, MD, 2007.
24. Qinghua S., and Adler I.D. Colcemid and econazole do not show aneugenicity in male mouse germ cells. Mutagenesis 13 (1998) 409-416
25. Gibson D.P., Aardema M.J., Kaerchert G.A., Carr G.J., Brauninger R.M., and LeBoeuf R.A. Detection of aneuploidy-inducing carcinogens in the Syrian hamster embryo (SHE) cell transformation assay. Mutat. Res. 343 (1995) 7-24
26. Migliore L., and Nieri M. Evaluation of twelve potential aneuploidogenic chemicals by the in vitro human lymphocyte micronucleus assay. Toxicol. In Vitro 5 (1991) 325-336
27. Hassan N.H. Miconazole genotoxicity in mice. J. Appl. Toxicol. 17 (1997) 313-319
28. Miconazole (Monograph) Mosby's Drug Consult, Miconazole, 17th ed. (2007) II 1917-II 1920, 16th edition, Mosby Elsevier, St. Louis, MO, 2006.
29. ®, 62nd ed., Thomson, Montvale, NJ, 2008, pp. 2980-2981.
30. Food and Drug Administration Center for Drug Evaluation and Research (CDER), From Food and Drug Administration, Summary for Basis of Approval (sba) for ketoconazole, Web site: http://www.fda.gov/cder/foi/nda/97/20310_NIZORAL%20A-D%201%25_pharmr.pdf.
31. Terconazole (Monograph) Mosby's Drug Consult, Terconazole, 17th ed. (2007) II 2739-II 2741, 16th edition, Mosby Elsevier, St. Louis, MO, 2006.
32. Fluconazole (Monograph) AHFS Drug Information 2008, Fluconazole 1 (2008) 500-511, American Society of Health-System Pharmacists, Bethesda, MD, 2007.
33. Dai T., Rashba-Step J., and Cederbaum A.I. Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 32 (1993) 6928-6937
34. Ekstrom G., and Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem. Pharmacol. 38 (1989) 1313-1319
35. Paulus G., Longeart L., and Monro A.M. Human carcinogenic risk assessment based on hormonal effects in a carcinogenicity study in rats with the antifungal agent, fluconazole. Teratog. Carcinog. Mutagen. 14 (1994) 251-257
36. Food and Drug Administration Center: Summary for Drug Evaluation and Research (CDER), From Food and Drug Administration, Basis of Approval (SBA) for voriconazole, Web site: http://www.fda.gov/cder/foi/nda/2002/21-266_21-267_Vfend.htm.
37. Voriconazole (Monograph). Mosby's Drug Consult, Voriconazole, 17th ed. (2007) II 2965-II 2974, 16th edition, Mosby Elsevier, St. Louis, MO, 2006.
38. Roe F.J. Liver tumors in rodents: extrapolation to man. Adv. Vet. Sci. Comp. Med. 31 (1987) 45-68
39. Bentley P., Clader I., Elcombe C., Grasso P., Stringer D., and Wiegand H.J. Hepatic peroxicome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31 (1993) 857-907
40. Parzefall W., Erber E., Sedivy R., and Schulte-Hermann R. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. Cancer Res. 51 (1991) 1143-1147
41. Itraconazole (Monograph), Mosby's Drug Consult, Itraconazole, 17th ed. (2007) II 1599-II 1612, 16th Edition, Mosby Elsevier, St. Louis, MO, 2006.
42. AHFS Drug Information 2008, Posaconazole, 1 (2008) 523-526, American Society of Health-System Pharmacists (Monograph), 16th edition, Mosby's Drug Consult, Bethesda, MD, 2006.